-
Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) released its 2023 financial report, recording HKD 1.4 billion (USD 193 million) in revenues, up 32.9% year-on-year (YOY). Licensed products continued to yield significant sales growth with HKD 553 million (USD 76 million), accounting for 39.5% of the total revenue. Patented and generic…
-
RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth
•
China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording RMB 1.717 billion (USD 236.3 million) in revenues, a 58.54% year-on-year (YOY) increase. Product sales reached RMB 1.699 billion (USD 233.9 million), up 61.9% YOY. The annual loss decreased by 2.8% YOY to RMB 1.468…
-
JW Therapeutics Sees 9% Revenue Decline in 2024 Amid Commercial Strategy Shift
•
China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD 21.8 million) in revenue, a 9% year-on-year (YOY) decline. This decrease was primarily due to the implementation of a commercial activity optimization strategy in the second half of 2024 and a business personnel organizational efficiency…
-
Ascentage Pharma’s Revenue Soars 342% in 2024 on Strong Drug Sales and Partnerships
•
China-based Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) unveiled its 2024 financials, showing revenues skyrocketing 342% year-on-year (YOY) to RMB980 million (USD135 million). This remarkable growth was primarily driven by an option payment from Japanese partner Takeda and robust sales of olverembatinib, the novel BCR-ABL1 tyrosine kinase inhibitor (TKI),…
-
Shanghai Pharmaceuticals Reports 5.75% Revenue Growth in 2024 with Innovation Initiatives
•
China’s Shanghai Pharmaceuticals (SPH; SHA: 601607, HKG: 2607) released its 2024 financial results, showing total revenues up 5.75% year-on-year (YOY) to RMB 275.251 billion (USD 37.9 billion). Pharmaceutical industry and business sales reached RMB 22.731 billion (USD 3.3 billion) and RMB 251.5 billion (USD 34.6 billion) respectively, with the latter…
-
YiChang HEC’s Yiqibuvir Approved by NMPA for Chronic HCV Infection
•
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG: 1558) announced receiving marketing approval from the National Medical Products Administration (NMPA) for its Category 1 drug yiqibuvir. The non-structural protein 5B (NS5B) inhibitor is approved for use in combination with netanasvir in adult chronic hepatitis C virus (HCV) infections of genotypes…
-
Luye Pharma’s Shandong Boan Bio Reports 17.5% Revenue Growth in 2024
•
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955) released its 2024 financial report, showing revenues growing 17.5% year-on-year (YOY) to RMB726.3 million (USD100 million). This growth was primarily driven by BA1101, a biosimilar of Roche’s Avastin (bevacizumab), and BA6101, a version of Amgen’s…
-
MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion
•
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch…
-
Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-1738 and HRS-5817 Clinical Trials
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical Products Administration (NMPA) to initiate clinical studies for its two Category 1 chemical drugs, HRS-1738 and HRS-5817, targeting prostate cancer and overweight/obesity respectively. HRS-1738: Prostate Cancer Diagnostic InnovationHRS-1738 is an internally developed radiopharmaceutical designed for in…
-
MicroPort MedBot Reports Strong 2024 Growth for Toumai and SkyWalker Robots
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) revealed its 2024 financial performance, recording RMB257 million (USD35 million) in revenues, a 146% year-on-year (YOY) increase. This growth was driven by the commercialization of the Toumai Laparoscopic Surgical Robot and SkyWalker Orthopedic Surgical Robot both domestically and internationally. Despite the revenue…
-
Sanofi’s mRNA Chlamydia Vaccine Gains FDA Fast Track Designation
•
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving fast track designation from the US Food and Drug Administration (FDA) for its mRNA vaccine candidate targeting the prevention of chlamydia infection. This designation represents a significant step forward in the development of the vaccine, which is designed to…
-
Fangzhou Inc. Partners with Tencent Health to Advance AI-Driven Healthcare Solutions
•
Guangzhou-based smart healthcare service platform Fangzhou Inc. (HKG: 6086) has announced a strategic partnership with China Internet giant Tencent’s Tencent Health and Tencent Cloud. The alliance aims to accelerate the development and implementation of AI-driven healthcare solutions by integrating the DeepSeek open-source AI Model on Fangzhou’s platform. Partnership DetailsThrough this…
-
Merck, Sharp & Dohme’s Capvaxive Approved by European Commission for Pneumococcal Prevention
•
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the European Commission (EC) approval for Capvaxive (Pneumococcal 21-valent conjugate vaccine). The vaccine is approved to prevent invasive disease and pneumonia caused by 21 different Streptococcus pneumoniae serotypes in adults: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A,…
-
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-9803 and SHR-A2102 Clinical Trials
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from the National Medical Products Administration (NMPA) for its anti-tumor drugs SHR-9803 and SHR-A2102. This marks a significant step forward in the development of these promising therapies. SHR-9803: Targeting Regulatory T CellsSHR-9803, a Category 1 biologic…
-
Servier and Black Diamond Therapeutics Ink Global Deal for Solid Tumor Targeted Therapy BDTX-4933
•
French pharmaceutical firm Servier has announced a global licensing agreement with US-based Black Diamond Therapeutics (NASDAQ: BDTX) concerning BDTX-4933, a small molecule targeted therapy for solid tumors. The deal underscores a significant collaboration aimed at advancing the treatment landscape for multiple cancer indications. Deal Structure and Financial TermsUnder the agreement,…
-
Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization
•
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s Laboratories Ltd. (BSE: 500124). The deal centers on Bio-Thera’s BAT2206, a biosimilar version of Stelara (ustekinumab), and BAT2506, a biosimilar version of Johnson & Johnson’s Simponi (golimumab). Dr. Reddy’s will gain exclusive rights to commercialize…
-
Shanghai Junshi Biosciences’ Loqtorzi Approved in Singapore for Nasopharyngeal Carcinoma
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval from the Singapore Health Sciences Authority (HSA) for its Loqtorzi (toripalimab). The anti-PD-1 monoclonal antibody (mAb) is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for recurrent, not amenable to surgery…
-
Zhejiang Funow Medicine Launches Triple Cream for Melasma Treatment in China
•
China-based Zhejiang Fonow Medicine Co., Ltd. (formerly known as: Zhejiang Rishengchang Pharmaceutical Co., Ltd.) has announced the official market launch of its fluocinolone acetonide, hydroquinone, and tretinoin cream in China for the treatment of melasma. This marks a significant advancement in the treatment landscape for this common pigmentation disorder. Innovative…
-
Luye Pharma’s BA1302 Receives FDA Orphan Drug Designation for Lung and Pancreatic Cancer
•
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955) has announced receiving orphan drug designation (ODD) from the US FDA for its novel antibody drug conjugate (ADC) BA1302. The designation covers two indications: squamous non-small cell lung cancer and pancreatic cancer. Innovative ADC DevelopmentBA1302,…
-
Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI
•
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot firm Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) to enhance antibody drug conjugate (ADC) product research and development (R&D). The partnership leverages the respective technical advantages of both companies in AI and ADC R&D fields,…
